March 22, 2021 09:54 AM EDT

Pfizer has run 41 trials over 15 years for tanezumab. As adcomm nears, the FDA remains unimpressed — and more than a little worried

Zachary Brennan

Senior Editor

Ahead of an advisory committee meeting later this week, the FDA on Monday released its in-depth review of Pfizer and Eli Lilly’s anti-NGF osteoarthritis drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pfizer has run 41 trials over 15 years for tanezumab. As adcomm nears, the FDA remains unimpressed — and more than a little worried

Zachary Brennan

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Trump says he'll sign order on 'most favored nation' drug price plans Monday

Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Pfiz­er has run 41 tri­als over 15 years for tanezum­ab. As ad­comm nears, the FDA re­mains unim­pressed — and more than a lit­tle wor­ried

Senior Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pfizer has run 41 trials over 15 years for tanezumab. As adcomm nears, the FDA remains unimpressed — and more than a little worried